ProGen announced on Wednesday that it will present the non-clinical results of its promising obesity drug candidate, PG-110, at the upcoming American Diabetes Association (ADA) conference in June. Designed to preserve muscle mass, PG-110 is a novel compound developed using ProGen’s NTIG platform.
PG-110 targets both the Activin receptor and Myostatin, key proteins involved in muscle growth. When combined with GLP-1 class drugs, PG-110 has shown promising results in promoting fat-specific weight loss and improving bone health.
Currently, GLP-1 drugs are leading the global obesity treatment market. However, significant unmet needs persist, including side effects such as muscle loss, gastrointestinal issues, and lower patient convenience.
ProGen is developing PG-110 to address these gaps. It will focus on healthy weight loss and improving patient convenience in treating obesity.
Kim Jong Kyun, CEO of ProGen, stated, “The results of the PG-110 study we’ll present at the ADA conference are part of our next-generation obesity treatment pipeline, following our obesity and diabetes drug PG-102, which is currently in Phase 2 clinical trials. We believe PG-110 could unlock new possibilities for managing obesity, especially in an aging population.”
In addition, ProGen is collaborating with Lani Therapeutics, a U.S.-based company, to co-develop an oral obesity treatment, RPG-102 (RT-114). The company plans to submit the Phase 1 clinical trial protocol to regulatory authorities in the first half of this year.